Try our Advanced Search for more refined results

Your firm must have an account to access this feature

Expert Analysis

A Change In Big Pharma Response To FTC Delisting Warnings

By Ratib Ali and Celia Lu ( September 2, 2025, 5:59 PM EDT) -- The Federal Trade Commission continues to be concerned about improper patent listings in the U.S. Food and Drug Administration's Orange Book, their deterrence of generic entry, and their consequent impact on prescription drug prices....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Companies

Government Agencies